相似文献
1
Understanding nanoparticle-liver interactions in nanomedicine.
Expert Opin Drug Deliv. 2024 Jun;21(6):829-843. doi: 10.1080/17425247.2024.2375400. Epub 2024 Jul 4.
2
Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory.
Mol Pharm. 2024 Jun 3;21(6):2970-2980. doi: 10.1021/acs.molpharmaceut.4c00097. Epub 2024 May 14.
3
Targeted delivery strategies: The interactions and applications of nanoparticles in liver diseases.
Biomed Pharmacother. 2024 Jun;175:116702. doi: 10.1016/j.biopha.2024.116702. Epub 2024 May 10.
4
Effect of removing Kupffer cells on nanoparticle tumor delivery.
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10871-E10880. doi: 10.1073/pnas.1713390114. Epub 2017 Dec 5.
5
Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist's perspectives.
Eur J Pharmacol. 2021 Feb 15;893:173832. doi: 10.1016/j.ejphar.2020.173832. Epub 2021 Jan 1.
6
Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination.
J Control Release. 2016 Oct 28;240:332-348. doi: 10.1016/j.jconrel.2016.01.020. Epub 2016 Jan 13.
7
Contribution of Kupffer cells to liposome accumulation in the liver.
Colloids Surf B Biointerfaces. 2017 Oct 1;158:356-362. doi: 10.1016/j.colsurfb.2017.07.014. Epub 2017 Jul 15.
8
The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Acc Chem Res. 2019 Jun 18;52(6):1507-1518. doi: 10.1021/acs.accounts.9b00126. Epub 2019 May 31.
9
Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
Drug Deliv Transl Res. 2020 Jun;10(3):766-790. doi: 10.1007/s13346-020-00744-1.
10
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine.
Adv Drug Deliv Rev. 2019 Mar 15;143:68-96. doi: 10.1016/j.addr.2019.04.008. Epub 2019 Apr 22.
引用本文的文献
1
Application of Nanotechnology in TACE Treatment of Liver Cancer.
Int J Nanomedicine. 2025 Aug 4;20:9621-9639. doi: 10.2147/IJN.S527518. eCollection 2025.
2
Application of nanomaterials in central nervous system disorders.
Psychopharmacology (Berl). 2025 Aug 8. doi: 10.1007/s00213-025-06862-3.
3
PEGylating AgS Semiconductor Nanocrystals for Pharmacokinetics Tracking: Insights from NIR Luminescence Imaging.
ACS Omega. 2025 Jun 26;10(26):28351-28361. doi: 10.1021/acsomega.5c03435. eCollection 2025 Jul 8.
4
Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism.
Int J Nanomedicine. 2025 May 30;20:6949-6962. doi: 10.2147/IJN.S515107. eCollection 2025.
5
Predictive Lung- and Spleen-Targeted mRNA Delivery with Biodegradable Ionizable Lipids in Four-Component LNPs.
Pharmaceutics. 2025 Apr 2;17(4):459. doi: 10.3390/pharmaceutics17040459.
6
Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment.
RNA Nanomed. 2024;1(1):109-123. doi: 10.59566/isrnn.2024.0101109.
7
Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism.
Mol Ther Methods Clin Dev. 2025 Feb 15;33(1):101436. doi: 10.1016/j.omtm.2025.101436. eCollection 2025 Mar 13.
8
Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.
Int J Mol Sci. 2025 Feb 18;26(4):1743. doi: 10.3390/ijms26041743.
9
A review on the role of nanoparticles for targeted brain drug delivery: synthesis, characterization, and applications.
EXCLI J. 2025 Jan 3;24:34-59. doi: 10.17179/excli2024-7163. eCollection 2025.
10
Recent advances in polymeric nanoparticles for the treatment of hepatic diseases.
Front Pharmacol. 2025 Jan 24;16:1528752. doi: 10.3389/fphar.2025.1528752. eCollection 2025.
本文引用的文献
1
Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles.
Adv Funct Mater. 2024 Feb 19;34(8). doi: 10.1002/adfm.202308446. Epub 2023 Nov 20.
2
PEGylated nanoparticles interact with macrophages independently of immune response factors and trigger a non-phagocytic, low-inflammatory response.
J Control Release. 2024 Feb;366:282-296. doi: 10.1016/j.jconrel.2023.12.019. Epub 2024 Jan 5.
3
Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease.
Acta Biomater. 2024 Jan 15;174:281-296. doi: 10.1016/j.actbio.2023.10.038. Epub 2023 Nov 10.
4
Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics.
Nat Nanotechnol. 2024 Feb;19(2):255-263. doi: 10.1038/s41565-023-01502-3. Epub 2023 Sep 18.
5
Drug delivery systems for CRISPR-based genome editors.
Nat Rev Drug Discov. 2023 Nov;22(11):875-894. doi: 10.1038/s41573-023-00762-x. Epub 2023 Sep 18.
6
Multivalent Targeting of the Asialoglycoprotein Receptor by Virus-Like Particles.
Small. 2023 Dec;19(52):e2304263. doi: 10.1002/smll.202304263. Epub 2023 Aug 30.
7
Lipid nanoparticles for siRNA delivery in cancer treatment.
J Control Release. 2023 Sep;361:130-146. doi: 10.1016/j.jconrel.2023.07.054. Epub 2023 Aug 4.
8
Where should siRNAs go: applicable organs for siRNA drugs.
Exp Mol Med. 2023 Jul;55(7):1283-1292. doi: 10.1038/s12276-023-00998-y. Epub 2023 Jul 10.
9
Histone demethylase KDM5D upregulation drives sex differences in colon cancer.
Nature. 2023 Jul;619(7970):632-639. doi: 10.1038/s41586-023-06254-7. Epub 2023 Jun 21.
10
Preliminary Structural Characterization of Selenium Nanoparticle Composites Modified by Polysaccharide and the Cytotoxicity Mechanism on Liver Cancer Cells.
Molecules. 2023 Feb 6;28(4):1561. doi: 10.3390/molecules28041561.
Zotero 插件